JPMorgan raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $35.00 (from $11.00) while maintaining a Overweight rating.

Analyst PT Change

Sangamo BioSciences (SGMO) PT Raised to $33 at JefferiesFebruary 23, 2018 8:58 AM Sangamo BioSciences (SGMO) PT Raised to $32 at Piper Jaffray, Remains Positive Citing Broadening PlatformFebruary 22, 2018 4:26 PM Sangamo BioSciences (SGMO) PT Raised to $39 at Wells FargoFebruary 22, 2018 12:23 PM Sangamo BioSciences (SGMO) PT Raised to $30 at BarclaysFebruary 22, 2018 11:56 AM Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3cFebruary 22, 2018 7:22 AM